Telapristone

Clinical data
Other names	CDB-4124; Proellex; Progenta; 17β-(Acetyloxy)-11β-[4-(dimethylamino)phenyl]-17α-(2-methoxyacetyl)estra-4,9-dien-3-one
Drug class	Selective progesterone receptor modulator
Legal status
Legal status	Investigational
Identifiers
IUPAC name [(8S,11R,13S,14S,17R)-11-[4-(Dimethylamino)phenyl]-17-(2-methoxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate
CAS Number	198414-31-2
PubChem CID	9806190
PubChem SID	347910049
DrugBank	DB05253 Y
ChemSpider	7981950 Y
UNII	1K9EYK92PQ
ChEMBL	ChEMBL2105694
CompTox Dashboard (EPA)	DTXSID60173587
Chemical and physical data
Formula	C31H39NO5
Molar mass	505.655 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C5\C=C3/C(=C2/[C@@H](c1ccc(N(C)C)cc1)C[C@@]4([C@@](OC(=O)C)(C(=O)COC)CC[C@H]4[C@@H]2CC3)C)CC5
InChI InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1 Y Key:JVBGZFRPTRKSBB-MJBQOYBXSA-N Y
(verify)

Telapristone (INNTooltip International Nonproprietary Name), as telapristone acetate (proposed brand names Proellex, Progenta; former code name CDB-4124), is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids.^[1][2] It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications.^[1] In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.^[3]